Rafael
Develops Trappsol Cyclo while holding healthcare, infusion-technology, and real-estate interests.
Something off on this page? Send us feedback.
Profile
Develops Trappsol Cyclo for Niemann-Pick disease type C, its lead clinical asset. The holding company also owns interests spanning healthcare, Day Three's Unlokt infusion technology, and a commercial real-estate property in Israel.
Develops Trappsol Cyclo, a clinical candidate for Niemann-Pick disease type C that became the lead asset after the Cyclo Therapeutics combination. The healthcare portfolio also includes majority interests in LipoMedix, Barer, Cornerstone, and Rafael Medical Devices.
The Infusion Technology segment holds a majority interest in Day Three and earns revenue from its Unlokt technology. Real Estate consists of a portion of one commercial building in Israel. Together, those operations retain the company's holding-company structure alongside its clinical program.
Howard S. Jonas controls shareholder voting power. The clinical trajectory depends on TransportNPC topline data and subsequent regulatory progress.
Company facts
Key statistics
Year to date +101% · Average volume (30d) 106.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026Q3 FY26 | — | −$0.15 | — | — | $179.0K | — | +5.66% |
| Mar 16, 2026Q2 FY26 | — | −$0.13 | — | — | $211.0K | — | +0.76% |
| Dec 11, 2025Q1 FY26 | — | −$0.19 | — | — | $240.0K | — | −2.01% |
| Oct 29, 2025Q4 FY25 | — | −$0.28 | — | — | $350.0K | — | +0.75% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $77.0K | $362.0K | $350.0K | $240.0K | $211.0K | $179.0K | |
| Gross profit | $39.0K | $322.0K | $281.0K | $231.0K | $144.0K | $171.0K | |
| Operating income | −$6.6M | −$5.9M | −$12.8M | −$10.1M | −$6.7M | −$6.9M | |
| Net income | −$4.6M | −$4.8M | −$12.1M | −$9.8M | −$6.4M | −$4.2M | |
| Diluted EPS | −$0.19 | −$0.19 | −$0.28 | −$0.19 | −$0.13 | −$0.08 | |
| Gross margin | 50.6% | 89.0% | 80.3% | 96.3% | 68.2% | 95.5% | |
| Operating margin | -8,622.1% | -1,633.4% | -3,646.6% | -4,225.4% | -3,154.0% | -3,838.0% |
Fiscal years (4-quarter sums)FY21 $3.2M · FY22 $410.0K · FY23 $279.0K · FY24 $637.0K · FY25 $917.0K
Balance sheet, Apr 30, 2026Cash & short-term investments $30.5M · Total debt $610.0K · Total assets $92.0M · Shareholders' equity $75.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 51.21M · Float 31.77M · 62.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| I9 Plus, LLC | 3.62M | 7.00% | 13D | Jun 9, 2025 |
| Vanguard Capital Management LLC | 1.37M | 2.67% | 13F | Aug 13, 2026 |
| Howard S. Jonas · director, 10 percent owner, officer: Exec Chairman, CEO & President | 836.2K | 1.63% | Form 4 | Jul 31, 2026 |
| Geode Capital Management, LLC | 429.9K | 0.84% | 13F | Aug 12, 2026 |
| BlackRock, Inc. | 390.1K | 0.76% | 13F | Aug 7, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Zevra Therapeutics
Approved NPC therapy MIPLYFFA, used with miglustat
- Johnson & Johnson
EU-authorised Zavesca for NPC neurological manifestations
- Stryker
Orthopaedic technologies overlapping minimally invasive instruments
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rafael | $2.59 | +2.37% | $131.1M | — | — | 133.8 | −50.6% |
| Zevra Therapeutics | $11.57 | +0.04% | $683.7M | 12.4 | 13.8 | 5.0 | +53.3% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Median | 31.1 | 20.6 | 5.0 | +9.4% |